IP Verse

Stable Pharmaceutical Composition And Methods Of Using Same - EP3278665

The patent EP3278665 was granted to Amarin Pharmaceuticals Ireland on Sep 9, 2020. The application was originally filed on Apr 29, 2010 under application number EP17168056A. The patent is currently recorded with a legal status of "Revoked".

EP3278665

AMARIN PHARMACEUTICALS IRELAND
Application Number
EP17168056A
Filing Date
Apr 29, 2010
Status
Revoked
Nov 11, 2022
Grant Date
Sep 9, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ELKINGTON AND FIFEJun 9, 2021- -

Patent Citations (11) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS2003195246
OPPOSITIONUS2006134178
OPPOSITIONUS2008200547
OPPOSITIONUS6193999
OPPOSITIONWO2010127103
OPPOSITIONWO2010147994
OPPOSITIONWO2013100089
SEARCHUS2006134178
SEARCHUS2008200547
SEARCHUS6193999
SEARCHWO2010147994

Non-Patent Literature (NPL) Citations (17) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BURTIS, ASHWOOD AND BORTER, Tietz Fundamentals of Clinical Chemistry, 6th ed., WB SAUNDERS COMPANY-
DESCRIPTION- YAMAZAKI ET AL., "Dissolution tests by RDC method for soft gelatin capsules containing ethyl icosapentate", PHARMACEUTICAL TECHNOLOGY JAPAN, (1999), vol. 15, pages 595 - 603, XP008162668-
OPPOSITION- "2.5.5. PEROXIDE VALUE", EUROPEAN PHARMACOPOEIA 6.0, (20080000), vol. Council of Europe, XP055815825-
OPPOSITION- "Chapter 5", FRANKEL, E. N. et al., Lipid Oxidation. 2nd ed., WP, (2005), XP055815821-
OPPOSITION- F S HOM et al., Soft Gelatin Capsules 11: Oxygen Permeability Study of Capsule Shells, (19750501), pages 851 - 857, URL: JOURNAL OF PHARMACEUTICAL SCIENCES, XP055178111-
OPPOSITION- GYARMATHY M, Selection from the industrial manufacturing, 5th part: Gelatine capsules. 5/2 part: Soft gelatine capsules, BUDAPEST, HU, (19940201), vol. 38, no. 2, ISSN 0017-6036, pages 106 - 109, XP009161931-
OPPOSITION- MOCHIDA PHARMACEUTICAL GROUP, Highlights of Our Growth-
OPPOSITION- Nochida, "Epadel S®", Nochida - Product Label, (20051100), pages 1 - 4, XP055815818-
OPPOSITION- PODCZECK FRIDRUN et al., Formulation and physical properties of soft capsules, (20040101), ISBN 978-0-85369-568-4, pages 201 - 212, XP008101385-
OPPOSITION- STEGEMANN, S et al., "Hard capsules today - and tomorrow", CAPSUGEL LIBRARY, (20020000), pages 1 - 23, URL: https://cpsl-web.s3.amazonaws.com/kc/library/hard-gelatin-capsules-today-and-tomorrow.pdf, XP008128828-
OPPOSITION- COLE et al., "Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration", ADVANCED DRUG DELIVERY REVIEWS, AMSTERDAM, NL, (20071221), vol. 60, no. 6, ISSN 0169-409X, pages 747 - 756, XP022476862
OPPOSITION- YOKOYAMA, M. et al., "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis", Lancet, (20070000), vol. 369, no. 9567, doi:10.1016/S0140-6736(07)60527-3, pages 1090 - 1098, XP022009572
OPPOSITION- HIGASHIHARA, E. et al., "The effect of eicosapentaenoic acid on renal function and volume in patients with ADPKD", Nephrol Dial Transplant, (20080327), vol. 23, no. 9, pages 2847 - 2852, XP055815814
SEARCH- F S HOM ET AL, "Soft Gelatin Capsules 11: Oxygen Permeability Study of Capsule Shells", JOURNAL OF PHARMACEUTICAL SCIENCES, (19750501), pages 851 - 857, XP055178111 [Y] 1-15 * page 854; table II and III * * page 854, column r, paragraph last - page 855, column l, paragraph first *-
SEARCH- GYARMATHY M, "Selection from the industrial manufacturing. 5th part: Gelatine capsules. 5/2 part: Soft gelatine capsules", GYOGYSZERESZET, MAGYAR GYOGYSZERESZETI TARSASAG, BUDAPEST, HU, (19940201), vol. 38, no. 2, ISSN 0017-6036, pages 105 - 109, XP009161931 [Y] 1-15 * page 105; table 1 *-
SEARCH- REICH G ED - PODCZECK FRIDRUN ET AL, Formulation and physical properties of soft capsules, Chapter 11, PHARMACEUTICAL CAPS, PHARMACEUTICAL PRESS, GB, PAGE(S) 201 - 212, (20040101), ISBN 978-0-85369-568-4, XP008101385 [Y] 1-15 * page 204, column l, paragraph 3 - column r, paragraph 1 * * page 206, column r, paragraph 2 *-
SEARCH- COLE ET AL, "Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, (20071221), vol. 60, no. 6, doi:10.1016/J.ADDR.2007.09.009, ISSN 0169-409X, pages 747 - 756, XP022476862 [Y] 1-15 * page 750, column r, paragraph 3 and 4 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents